Compare BODI & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BODI | GRML |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 29.2M |
| IPO Year | 2020 | 2022 |
| Metric | BODI | GRML |
|---|---|---|
| Price | $4.44 | $5.86 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | 13.3K | ★ 6.0M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.10 | 31.25 |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $251,727,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.09 | N/A |
| P/E Ratio | $9.18 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.05 | $0.16 |
| 52 Week High | $16.87 | $18.21 |
| Indicator | BODI | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | 47.10 |
| Support Level | N/A | $0.28 |
| Resistance Level | $5.11 | $7.53 |
| Average True Range (ATR) | 0.19 | 0.85 |
| MACD | 0.04 | -0.28 |
| Stochastic Oscillator | 21.74 | 34.48 |
The Beachbody Co Inc is a fitness and nutrition company providing fitness, nutrition, and stress-reducing programs to its customers. a results-oriented company at the intersection of wellness, technology, and media. The company developed one of the original fitness digital streaming platforms with an extensive library of content containing streaming programs and streaming videos. Company products include Digital Subscriptions, Nutritional Products, and Connected Fitness Products, where the majority of revenue is from Digital Subscriptions. The Company has one operating and reporting segment. Geographically operates in the USA and the rest of the world, with maximum revenue from the United States.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.